Why do patients fail HIV therapy?

Despite huge advances in terms of the impact of antiretroviral therapy on HIV‐related morbidity and mortality patients continue to fail therapy. We discuss the reasons why failure occurs including primary or transmitted resistance, poor adherence, toxicity and drug potency. We performed a review of PubMed, Medline and recent conference abstracts for information on antiretroviral toxicity, adherence, failure and transmitted resistance. Most first‐line regimens are now similar in potency and, assuming susceptibility to the selected regimen determined by genotypic resistance testing, tolerability and toxicity are the key issues differentiating currently available agents. New developments such as pharmacogenomics have already proven useful in predicting toxicity and may play an increasingly important role. With all regimens good adherence remains the key to successful therapy; minimising toxicity and other barriers to adherence wherever possible is crucial.

[1]  G. Moyle.  The Assessing Patients’ Preferred Treatments (APPT-1) study , 2003, International journal of STD & AIDS.

[2]  B. Gazzard,et al.  Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial , 2005, AIDS.

[3]  P. Barton,et al.  Antidepressant Treatment Improves Adherence to Antiretroviral Therapy Among Depressed HIV-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[4]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[5]  F. Brun-Vézinet,et al.  French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002 , 2005, Journal of acquired immune deficiency syndromes.

[6]  P. Reiss,et al.  Prevalence of Lipoatrophy and Mitochondrial DNA Content of Blood and Subcutaneous Fat in HIV-1-Infected Patients Randomly Allocated to Zidovudine- or Stavudine-Based Therapy , 2003, Antiviral therapy.

[7]  B. Kearney,et al.  Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine , 2005, Journal of clinical pharmacology.

[8]  K. Metzner.  Detection and significance of minority quasispecies of drug-resistant HIV-1. , 2006, Journal of HIV therapy.

[9]  F. Caciagli,et al.  Antidepressant Therapy Can Improve Adherence to Antiretroviral Regimens Among HIV-Infected and Depressed Patients , 2007, Journal of clinical psychopharmacology.

[10]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[11]  S. Mallal,et al.  Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Katlama,et al.  The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.

[13]  E. Vittinghoff,et al.  Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance , 2007, AIDS.

[14]  N. Schneiderman,et al.  Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. , 1998, Psychiatric services.

[15]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[16]  G. Garber,et al.  A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART , 2006, AIDS care.

[17]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[18]  B. Gazzard,et al.  Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. , 2005, The Journal of antimicrobial chemotherapy.

[19]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[20]  Hauke Walter,et al.  Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.

[21]  A. Ray,et al.  Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir , 2004, Antimicrobial Agents and Chemotherapy.

[22]  B. Gazzard,et al.  The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily , 2005, HIV medicine.

[23]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[24]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[25]  T. Pumarola,et al.  High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir , 2005, AIDS.

[26]  Steve A Castillo,et al.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Neaton,et al.  Grade 4 Events Are as Important as AIDS Events in the Era of HAART , 2003, Journal of acquired immune deficiency syndromes.

[28]  M. Juan,et al.  Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load , 2004, AIDS.

[29]  Richard D Moore,et al.  Hazardous Alcohol Use: A Risk Factor for Non-Adherence and Lack of Suppression in HIV Infection , 2006, Journal of acquired immune deficiency syndromes.

[30]  A. Wu,et al.  Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART , 2003, HIV clinical trials.

[31]  C. Moore,et al.  HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2022 .

[32]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[33]  Felipe García,et al.  Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults , 2004, The Lancet.

[34]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[35]  Antiretroviral resistance. , 2006, Journal of HIV therapy.

[36]  D. Cooper,et al.  Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study , 2004, AIDS.

[37]  B. Gazzard,et al.  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.

[38]  M. Markowitz,et al.  Induction With Abacavir/Lamivudine/Zidovudine Plus Efavirenz for 48 Weeks Followed by 48-Week Maintenance With Abacavir/Lamivudine/Zidovudine Alone in Antiretroviral-Naive HIV-1-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[39]  C. Farthing,et al.  Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. , 2005, AIDS patient care and STDs.

[40]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[41]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[42]  M. Johnson,et al.  96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures , 2006, AIDS.

[43]  M. Wainberg,et al.  Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection , 2004, AIDS.

[44]  V. Soriano,et al.  Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Sauret,et al.  Improvements in facial lipoatrophy at 48 weeks following substitution of a thymidine analogue with tenofovir (TDF) or abacavir (ABC): a randomized, open-label study in people with lipoatrophy and virological suppression on HAART , 2005 .

[46]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[47]  P. Kissinger,et al.  Patterns and Correlates of Discontinuation of the Initial HAART Regimen in an Urban Outpatient Cohort , 2003, Journal of acquired immune deficiency syndromes.

[48]  J. Moatti,et al.  Factors Associated With Nonadherence to Highly Active Antiretroviral Therapy: A 5-Year Follow-Up Analysis With Correction for the Bias Induced by Missing Data in the Treatment Maintenance Phase , 2006, Journal of acquired immune deficiency syndromes.

[49]  B. Clotet,et al.  Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients , 2005, Antimicrobial Agents and Chemotherapy.

[50]  J. Gallant,et al.  Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. , 2005, The Journal of infectious diseases.

[51]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[52]  J. Phair,et al.  Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  P. Anderson,et al.  CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. , 2004, AIDS.

[54]  D. Podzamczer,et al.  Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz , 2005, Antiviral therapy.

[55]  G. Colfax,et al.  Club drugs and HIV infection: a review. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.